Recognition places pharmaceutical excipients leader among the top 5% of companies globally, highlighting progress in emissions reduction, responsible sourcing, and sustainable supply chain practices
The company says the goal is to improve consistency and efficiency in total hip arthroplasty (THA) as demand for the procedure continues to surge
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
Broadening access for children & patients with inhibitor-complicated hemophilia
The company will present 21 oral and poster presentations spanning investigational and approved therapies
We are building the bridge between complex molecular data and everyday clinical decisions
Subscribe To Our Newsletter & Stay Updated
